NR 566 / NR566 Advanced Pharmacology

Care of the Family Midterm Review|

LATEST 2021 /2022 | Chamberlain

College

1. How to measure therapeutic effect of HIV therapy

- RNA LEVELS

obaseline

o2-4 weeks, no later than 8 weeks

oevery 4-8 weeks until suppressed

oafter suppressed every 3-4 months

- Long-term virologic suppression x2 years

oevery 6 months

- any change in status = chemo/steroids

oevery 3 months

2. Protease Inhibitor (PIs) Lopinavir - high risk patients

- ORAL solution: Contraindicated for full-term infants (until 14 days after

birth) and premature (until 14 days after due date)

ocardiac disease

oHx prolong QT

3. Protease Inhibitor (PIs) Lopinavir - Lifespan considerations

- Children: Safe after 14 days old 

- Pregnancy: approved w/ higher risks

4. Protease Inhibitor (PIs) Lopinavir/ritonavir - adverse effects

- - QT prolongation

5. Protease Inhibitor (PIs) Saquinavir - Lifespan considerations

- Children

o Not identified as safe/efficient in children younger than 16

- Pregnancy

oSafest PI for pregnancy

- HIV treatment is recommended in pregnancy

6. Protease Inhibitor (PIs) Saquinavir - adverse reactions

- - QT prolongation

7. Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs). Didanosine (ddI) - high

risk patient

- Increase risk of pancreatitis with alcohol use, pancreatitis, and IV pentamide

8. Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs). Didanosine (ddI) -

Lifespan considerations

- Children

oapproved in 6 years + weighing 20kg

- Pregnancy

oLess risk

9. Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs). Zidovudine - Lifespan

consideration

- Children

oneonates

- Pregnancy

oincreased risk

10. Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs): Zidovudine - high risk

patients

- Hx of

ogranulocytosis

olow H&H

olow vit B12

olow folic acid

ocurrent use of meds that cause myelosuppe

11. How to measure therapeutic effect of HIV therapy

- CD4 counts

o w/ suppressed RNA levels = increase CD4 levels

- Check levels

obaseline

oat 3 month mark

oduring 1st 2 years every 3-6 months during therapy

olong-term suppression

- CD4 <300 = every 3-6 months

- CD4 consistently b/w 300-500 = every 12 months

- CD4 >500 = optional